Welcome to CDC stacks | Impact of recent innovations in the use of mass cytometry in support of drug development - 36266 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Impact of recent innovations in the use of mass cytometry in support of drug development
Filetype[PDF-329.87 KB]


Details:
  • Personal Authors:
  • Pubmed ID:
    26092491
  • Pubmed Central ID:
    PMC4668584
  • Description:
    Cytometry by time-of-flight (CyTOF) is a novel technology for the real-time analysis of single cells. CyTOF is a significant advance in fields including immunology, hematology, and oncology. It resolves multiple metal-conjugated probes per cell with minimal signal overlap, which maximizes the information obtained from each individual sample. CyTOF provides the ability to phenotypically and functionally profile cells from normal and diseased states. Single cell technologies enable researchers to measure the effects of a drug at the single cell level and better understand its mechanism of action. Here, we discuss novel instruments for the analysis of individual biological cells, the impact of recent innovations in support of drug development, and the important roles of CyTOF in drug profiling.

  • Document Type:
    Journal Article
  • Collection(s):
    CDC Public Access
  • Funding:
    R21 OH010438/OH/NIOSH CDC HHS/United States
    R21 OH010494/OH/NIOSH CDC HHS/United States
No Related Documents.
You May Also Like:
  1. Automation of sample preparation for mass cytometry barcoding in support of clinical research: protocol optimization
    Personal Author:
    Nassar, Ala F.; Wisnewski, Adam V.; Raddassi, Khadir;
    Published:
    Jan 26 2017
    Source:
    Anal Bioanal Chem. 409(9):2363-2372.
    Description:
    Analysis of multiplexed assays is highly important for clinical diagnostics and other analytical applications. Mass cytometry enables multi-dimensional, single-cell analysis of cell type and state. In mass cytometry, the rare earth metals used as rep...
    File Type:
    Filetype[PDF - 2.08 MB]
  2. Toward the Responsible Development and Commercialization of Sensor Nanotechnologies
    Personal Author:
    Fadel, Tarek R.; Farrell, Dorothy F.; Friedersdorf, Lisa E.; Griep, Mark H.; Hoover, Mark D.; Meador, Michael A.; Meyyappan, M.;
    Published:
    Feb 25 2016
    Source:
    ACS Sens. 1(3):207-216.
    Description:
    Nanotechnology-enabled sensors (or nanosensors) will play an important role in enabling the progression toward ubiquitous information systems as the Internet of Things (IoT) emerges. Nanosensors offer new, miniaturized solutions in physiochemical and...
    File Type:
    Filetype[PDF - 1.01 MB]
  3. Effect of mucosal cytokine administration on selective expansion of vaginal dendritic cells to support nanoparticle transport
    Personal Author:
    Ramanathan, R.; Park, J.; Hughes, S.M.; Lykins, W.R.; Bennett, H.R.; Hladik, F.; Woodrow, K.A.;
    Published:
    Jun 27 2015
    Source:
    Am J Reprod Immunol. 74(4):333-344.
    Description:
    Problem : The capacity of antigen-carrying vaccine nanoparticles administered vaginally to stimulate local immune responses may be limited by the relatively low numbers of antigen-presenting cells (APCs) in the genital mucosa. Because inflammation is...
    File Type:
    Filetype[PDF - 1.11 MB]
  4. Minor changes in expression of the mismatch repair protein MSH2 exert a major impact on glioblastoma response to temozolomide
    Personal Author:
    McFaline-Figueroa, José L.; Braun, Christian J.; Stanciu, Monica; Nagel, Zachary D.; Mazzucato, Patrizia; Sangaraju, Dewakar; Cerniauskas, Edvinas; Barford, Kelly; Vargas, Amanda; Chen, Yimin; Tretyakova, Natalia; Lees, Jacqueline A.; Hemann, Michael T.; White, Forest M.; Samson, Leona D.;
    Published:
    May 29 2015
    Source:
    Cancer Res. 75(15):3127-3138.
    Description:
    Glioblastoma (GBM) is often treated with the cytotoxic drug temozolomide, but the disease inevitably recurs in a drug-resistant form after initial treatment. Here, we report that in GBM cells, even a modest decrease in the mismatch repair (MMR) compo...
    File Type:
    Filetype[PDF - 1.70 MB]
  5. Biological frontiers in multiple myeloma: From biomarker identification to clinical practice
    Personal Author:
    Landgren, Ola; Morgan, Gareth J.;
    Published:
    Nov 22 2013
    Source:
    Clin Cancer Res. 20(4):804-813.
    Description:
    Since the mid-1990s, the multiple myeloma treatment landscape has evolved considerably, which has led to improved patient outcomes and prolonged survival. In addition to discovering new, targeted agents or treatment regimens, the identification and v...
    File Type:
    Filetype[PDF - 420.37 KB]